Manifexo Tablet is a combination medication containing Montelukast 10 mg and Fexofenadine 120 mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, works by blocking leukotrienes, which are inflammatory mediators responsible for symptoms like bronchoconstriction, mucus production, and airway edema. Fexofenadine, a second-generation antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing histamine-induced allergic symptoms including sneezing, nasal congestion, itching, and hives without causing significant sedation. The synergistic action of these two agents provides comprehensive relief from both early and late-phase allergic responses. Manifexo is indicated for patients requiring effective control of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria, improving quality of life by alleviating nasal and skin symptoms. It is generally well-tolerated, with a low incidence of adverse effects such as headache, dizziness, or gastrointestinal disturbances. Caution is advised in patients with hepatic impairment and those on concomitant medications that may interact. Manifexo Tablet should be used under medical supervision, adhering to prescribed dosages to ensure optimal therapeutic outcomes and minimize potential risks.